Page 28 - Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

Biyolojik Ajan Kullanan Romatolojik Hastalarda Enfeksiyon Yönetimi

14. Zanger P, Kötter I, Kremsner PG, Gabrysch S. Tumor necrosis factor 31. Akgul O, Ozgocmen S. Infliximab and brucellosis: not the usual suspe-
alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol cts, this time. Mod Rheumatol 2011;21:313-5.
Infect 2012;18:670-6. 32. Candel FJ, Peñuelas M, Tabares C, Garcia-Vidal C, Matesanz M, Salavert
15. Xynos LD, Tektonidou MG, Pikazis D, Sipsas NV. Leishmaniasis, auto- M, et al. Fungal infections following treatment with monoclonal anti-
immune rheumatic disease, and anti-tumor necrosis factor therapy, bodies and other immunomodulatory therapies. Rev Iberoam Micol
Europe. Emerg Infect Dis 15(6);956-9. 2020 Jan-Mar;37(1):5-16.
16. Guedes-Barbosa LS, Pereira da Costa I, Fernandes V, Henrique da 33. Smith JA. Tumor necrosis factor inhibitors and fungal infections. Curr
Mota LM, de Menezes I, Aaron Scheinberg M. Leishmaniasis during Fungal Infect Rep 2010;4:38-45.
anti-tumor necrosis factor therapy: report of 4 cases and review of 34. Park H, Solis NV, Louie JS, Spellberg B, Rodriguez N, Filler SG. Diffe-
the literature (additional 28 cases). Semin Arthritis Rheum 2013 rent tumor necrosis factor α antagonists have different effects on
Oct;43(2):152-7. host susceptibility to disseminated and oropharyngeal candidiasis in
17. Manolios N, Burneikis A, Spencer D, Howe G. Failure of anti-TNF the- mice. Virulence 2014;5(5):625-9.
rapy to reactivate previously septic prosthetic joints. BMJ Case Rep 35. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infec-
2013 Jul 8;2013:pii: bcr2013009827. tions complicating tumor necrosis factor alpha blockade therapy.
18. Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cy- Mayo Clin Proc 2008 Feb;83(2):181-94.
tomegalovirus infection. Infect Disord Drug Targets. 2011;11(5):466-74. 36. Galli M, Antinori S, Atzeni F. Recommendations for the management
19. Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, et al. Cytomega- of pulmonary fungal infections in patients with rheumatoid arthritis.
lovirus colitis in a patient with Behcet’s disease receiving tumor Clin Exp Rheumatol 2017;35(6):1018-28.
necrosis factor alpha inhibitory treatment. World J Gastroenterol 37. Fraison JB, Guilpain P, Schiffmann A. Pulmonary cryptococcosis in a
2008;14(18):2912-4. patient with Crohn’s disease treated with prednisone, azathioprine
20. Paz SPC, Branco L, Pereira MAC, Spessotto C, Fragoso YD. Systematic and adalimumab: exposure to chicken manure as a source of conta-
review of the published data on the worldwide prevalence of John mination. J Crohns Colitis 2013;7(1):e11-e14.
Cunningham virus in patients with multiple sclerosis and neuromye- 38. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec
litis optica. Epidemiol Health 2018;40:e2018001. L, et al. COVID-19 Global Rheumatology Alliance. Characteristics as-
21. Nosaki Y, Ohyama K, Watanabe M, Yokoi T, Nakamichi K, Saijo M, et al. sociated with hospitalisation for COVID-19 in people with rheumatic
Simultaneous development of progressive multifocal leukoencepha- disease: data from the COVID-19 Global Rheumatology Alliance phy-
lopathy and cryptococcal meningitis during methotrexate and ınflixi- sician-reported registry. Ann Rheum Dis 2020 Jul;79(7):859-66.
mab treatment. Intern Med 58 2019;(18):2703-9. 39. Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, et al. Lymphocyte
22. Pietropaolo V, Prezioso C, Bagnato F, Antonelli G. John Cunningham subset (CD4+, CD8+) counts reflect the severity of infection and pre-
virus: an overview on biology and disease of the etiological agent of dict the clinical outcomes in patients with COVID-19. J Infect 2020
the progressive multifocal leukoencephalopathy. New Microbiologi- Aug;81(2):318-356.
ca 2018;(41)3:179-86. 40. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergenta-
23. Cruz Fernández-Espartero M, Pérez-Zafrilla B, Naranjo A, Esteban C, nis TN, Politou M, Psaltopoulou T,et al. Hematological findings and
Ortiz AM, Gomez-Reino JJ, et al. Demyelinating disease in patients complications of COVID-19. Am J Hematol 2020 Jul;95(7):834-47.
treated with TNF antagonists in rheumatology: data from BIOBADA- 41. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and Func-
SER, a pharmacovigilance database, and a systematic review. Semin tional Exhaustion of T Cells in Patients with Coronavirus Disease 2019
Arthritis Rheum 2011;41(3):524-33. (COVID-19). Front Immunol 2020 May 1;11:827.
24. Ferreira AM, Ramos JF, Fatobene G, Rocha V. Pneumocystis jirove- 42. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune
cii pneumonia during brentuximab vedotin therapy: A case report system response, hyperinflammation and repurposing antirheumatic
and literature review. Case Reports in Hematology 2019, Article ID drugs. Turk J Med Sci 2020 Apr 21;50(SI-1):620-632.
8982937, 3 pages.
43. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. CO-
25. Mori S, Sugimoto M. Pneumocystis jirovecii infection: an emer- VID-19 infection and rheumatoid arthritis: Faraway, so close! Autoim-
ging threat to patients with rheumatoid arthritis. Rheumatology mun Rev. 2020 May;19(5):102523. doi: 10.1016/j.autrev.2020.102523.
2012;51:2120-30.
44. T.C. SAĞLIK BAKANLIĞI. 2020. Antisitokin-Antiinflamatuvar Tedaviler,
26. Mikulska M, Lanini S, Gudiol C. ESCMID Study Group for Infections in Koagülopati Yönetimi, 07 Kasım 2020. https://covid19.saglik.gov.tr/
Compromised Hosts (ESGICH) consensus document on the safety of TR-66341/antisitokin-antiinflamatuvar-tedaviler-koagulopati-yoneti-
targeted and biological therapies: an infectious diseases perspective mi.html
(agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and
CD52). Clin Microbiol Infect 2018; 24(suppl 2):S71–S82. 45. COVID-19 Tanı ve Tedavisinde Kanıta Dayalı Öneriler ve Türk Toraks
Derneği COVID-19 Görev Grubu Görüş Raporu, Türk Toraks Derneği
27. Winthrop K, Mariette X, Silva J, Benamu E, Calabrese LH, Dumusc A, COVID-19 E-Kitapları Serisi, Aralık 2020. ISBN: 978-605-06717-4-2.
et al. ESCMID Study Group for Infections in Compromised Hosts (ES-
GICH) consensus document on the safety of targeted and biological 46. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I,
therapies: an infectious diseases perspective (soluble immune effector et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet
molecules [II]: agents targeting interleukins, immunoglobulins and Rheumatol 2020 Jul;2(7):e393-e400.
complement factors). Clin Microbiol Infect 2018; 24(suppl 2):S21–S40. 47. Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK.
Use of Anakinra to Prevent Mechanical Ventilation in Severe CO-
28. Kutlu M, Ergin Ç, Şen-Türk N, Sayin-Kutlu S, Zorbozan O, Akalın Ş, et al.
Acute Brucella melitensis M16 infection model in mice treated with tu- VID-19: A Case Series. Arthritis Rheumatol 2020 Dec;72(12):1990-7.
mor necrosis factor-alpha inhibitors. J Infect Dev Ctries 2015; 9(2):141-8. 48. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M,
et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are
29. Jiménez FG, Colmenero JD, Irigoyen MV. Reactivation of brucellosis
after treatment with infliximab in a patient with rheumatoid arthritis. urgently needed. Lancet 2020 May 2;395(10234):1407-9.
J Infect 2005;50:370-1. 49. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ pers-
pective on coronavirus disease 19 (COVID-19) and potential thera-
30. Papagoras CE, Argyropoulou MI, Voulgari PV, Vrabie I, Zikou AK, Dro-
sos AA. A case of Brucella spondylitis in a patient with psoriatic arthri- peutic targets. Clin Rheumatol 2020 Jul;39(7):2055-62.
tis receiving infliximab. Clin Exp Rheumatol 2009;27:124-7.
18